Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression
J. Jankowski, … , W. Zidek, M. Tepel
J. Jankowski, … , W. Zidek, M. Tepel
Published July 15, 2003
Citation Information: J Clin Invest. 2003;112(2):256-264. https://doi.org/10.1172/JCI15524.
View: Text | PDF
Article Endocrinology

Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression

  • Text
  • PDF
Abstract

NO prevents atherogenesis and inflammation in vessel walls by inhibition of cell proliferation and cytokine-induced endothelial expression of adhesion molecules and proinflammatory cytokines. Reduced NO production due to inhibition of either eNOS or iNOS may therefore reinforce atherosclerosis. Patients with end-stage renal failure show markedly increased mortality due to atherosclerosis. In the present study we tested the hypothesis that uremic toxins are responsible for reduced iNOS expression. LPS-induced iNOS expression in mononuclear leukocytes was studied using real-time PCR. The iNOS expression was blocked by addition of plasma from patients with end-stage renal failure, whereas plasma from healthy controls had no effect. Hemofiltrate obtained from patients with end-stage renal failure was fractionated by chromatographic methods. The chromatographic procedures revealed a homogenous fraction that inhibits iNOS expression. Using gas chromatography/mass spectrometry, this inhibitor was identified as phenylacetic acid. Authentic phenylacetic acid inhibited iNOS expression in a dose-dependent manner. In healthy control subjects, plasma concentrations were below the detection level, whereas patients with end-stage renal failure had a phenylacetic acid concentration of 3.49 ± 0.33 mmol/l (n = 41). It is concluded that accumulation of phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. That mechanism may contribute to increased atherosclerosis and cardiovascular morbidity in patients with end-stage renal failure.

Authors

J. Jankowski, M. van der Giet, V. Jankowski, S. Schmidt, M. Hemeier, B. Mahn, G. Giebing, M. Tölle, H. Luftmann, H. Schlüter, W. Zidek, M. Tepel

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Plasma from patients with end-stage renal failure and healthy control su...
Plasma from patients with end-stage renal failure and healthy control subjects show effects of PAA and some of its derivatives on iNOS mRNA expression measured by real-time PCR without (basal; set to 100%) and after stimulation by LPS (1 μg/ml) and IFN-γ (100 U/ml) (control) in mononuclear leukocytes. (a) Expression of iNOS in the presence of various amounts of plasma diluted in PBS from patients with CRF on regular hemodialysis (end-stage renal failure) in the presence of plasmas from healthy persons (healthy). The plasma was diluted with physiologic salt solution 1/10, 1/2, and 1/1, respectively. Basal unstimulated iNOS expression was set to 100%; each n = 6. (b) Expression iNOS in the presence of various concentrations of PAA (0.05 mmol/l, 0.1 mmol/l, 0.5 mmol/l, 1.0 mmol/l, and 2.0 mmol/l). Control value as in a. Basal unstimulated iNOS expression was set to 100%. (c) Expression of iNOS in the presence of homogentisic acid (HGA; 1.0 mmol/l), phenylethyl amine (PEA; 1.0 mmol/l), or phenylalanine (PhA; 1.0 mmol/l) (n = 6). *P < 0.05 compared with control.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts